Related references
Note: Only part of the references are listed.Quantitative determination of Cpd118, A novel FBPase inhibitor, in dog plasma by HPLC-MS/MS
Jinping Hu et al.
BIOANALYSIS (2021)
Identification of the New Covalent Allosteric Binding Site of Fructose-1,6-bisphosphatase with Disulfiram Derivatives toward Glucose Reduction
Yunyuan Huang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Development of disulfide-derived fructose-1,6-bisphosphatase (FBPase) covalent inhibitors for the treatment of type 2 diabetes
Yi-xiang Xu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discovery of N-Arylsulfonyl-Indole-2-Carboxamide Derivatives as Potent, Selective, and Orally Bioavailable Fructose-1,6-Bisphosphatase Inhibitors-Design, Synthesis, In Vivo Glucose Lowering Effects, and X-ray Crystal Complex Analysis
Jie Zhou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Development of a protein-ligand extended connectivity (PLEC) fingerprint and its application for binding affinity predictions
Maciej Wojcikowski et al.
BIOINFORMATICS (2019)
Discovery of novel allosteric site and covalent inhibitors of FBPase with potent hypoglycemic effects
Yunyuan Huang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Fructose-1,6-bisphosphatase inhibitors: A new valid approach for management of type 2 diabetes mellitus
Ramandeep Kaur et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Discovery of novel indole derivatives as allosteric inhibitors of fructose-1,6-bisphosphatase
Jianbo Bie et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2015)
Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people
Anoop Dinesh Shah et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
Design, synthesis and biological evaluation of 7-nitro-1H-indole-2-carboxylic acid derivatives as allosteric inhibitors of fructose-1,6-bisphosphatase
Jianbo Bie et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2014)
Endothelial nitric oxide synthase (eNOS) 4b/a polymorphism and the risk of diabetic nephropathy in type 2 diabetes mellitus: A meta-analysis
Ze-jun Ma et al.
META GENE (2014)
Discovery of a Series of Phosphonic Acid-Containing Thiazoles and Orally Bioavailable Diamide Prodrugs That Lower Glucose in Diabetic Animals Through Inhibition of Fructose-1,6-Bisphosphatase
Qun Dang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Structure-based drug design of tricyclic 8H-indeno[1,2-d][1,3]thiazoles as potent FBPase inhibitors
Tomoharu Tsukada et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Rational Design, Synthesis, and Potency of N-Substituted Indoles, Pyrroles, and Triarylpyrazoles as Potential Fructose 1,6-Bisphosphatase Inhibitors
Aleksandra Rudnitskaya et al.
CHEMMEDCHEM (2010)
Designing inhibitors against fructose 1,6-bisphosphatase: Exploring natural products for novel inhibitor scaffolds
Sabrina Heng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2010)
A library of novel allosteric inhibitors against fructose 1,6-bisphosphatase
Sabrina Heng et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2009)
Synthesis, SAR, and X-ray structure of tricyclic compounds as potent FBPase inhibitors
Tomoharu Tsukada et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Fructose-1,6-bisphosphatase overexpression in pancreatic β-cells results in reduced insulin secretion -: A new mechanism for fat-induced impairment of β-cell function
Melkam Kebede et al.
DIABETES (2008)
The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes - Results from Metascreen, a multicenter diabetes clinic-based survey
Riccarcdo C. Bonadonna et al.
DIABETES CARE (2006)
MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes
MD Erion et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)